Palvella Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ____________ to ____________Commission File Number 001-37471 Palvella Therapeutics, Inc.(Exact name of Registrant as specified in its Charter) Nevada30-0784346(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)353 W. Lancaster Ave, Suite 200Wayne, Pennsylvania19087(Address of principal executive offices)(Zip Code)Registrant’s telephone number, including area code: (484) 253-1461 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ The number of shares of Registrant’s common stock outstanding as of July 31, 2026 was 14,408,407. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six MonthsEnded June 30, 2026 and 20252Condensed Consolidated Statements of Changes in Preferred Stock and Stockholders’ Equity (Deficit) for theThree and Six Months Ended June 30, 2026 and 20253Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 20255Notes to Unaudited Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk33Item 4.Controls and Procedures33 PART II. OTHER INFORMATIONItem 1.Legal Proceedings 3535 Item 1A.Risk Factors35Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchase of Equity Securities35Item 3.Defaults Upon Senior Securities35Item 4.Mine Safety Disclosures35Item 5.Other Information35Item 6.Exhibits37 SIGNATURES GENERAL INFORMATION Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Palvella,” the“company,” the “Company,” “we,” “us,” “our” or similar designations refer to Palvella Therapeutics, Inc. (formerly PierisPharmaceuticals, Inc.) and its subsidiaries, taken together. All trademarks, service marks, trade names and registered marks used inthis report are trademarks, trade names or registered marks of their respective owners. References to “Pieris” refer to Pieris Pharmaceuticals, Inc., our predecessor company prior to the Merger (as defined below) andreferences to “Legacy Palvella” or “Palvella” refer to Palvella Therapeutics, Inc. prior to the Merger and our wholly ownedsubsidiary upon the consummation of the Merger (as defined below). On December 13, 2024 (the “Closing Date”), Palvella Therapeutics, Inc., a Nevada corporation (the “Company” or “Palvella”)(previously named Pieris Pharmaceuticals, Inc. and our predecessor company (“Pieris”)), consummated the previously announcedmerger pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the “Merger Agreement”),by and among the Company, Polo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Pieris (the “MergerSub”), and Palvella Therapeutics, Inc., a Delaware corporation (“Legacy Palvella”). Pursuant to the Merger Agreement, on theClosing Date, (i) Merger Sub merged with and into Legacy Palvella, with Legacy Palvella as the